Wax Selection – Leaders in Pharma, Biotech & MedTech Recruitment
French pharma firm Ipsen has announced the appointment of Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic Area and Dr. Alexander “Sandy” McEwan, as Vice President, Head of Radiopharmaceuticals.
It is hoped that the move, which has seen the company take on two leading oncology specialists within a month of each other, will strengthen the company’s oncology arm.
Alexandre Lebeaut, Executive Vice President R&D and Chief Scientific Officer, Ipsen, commented: “I am thrilled to welcome Yan and Sandy as talented leaders who will assume pivotal roles in the next phase of our R&D transformation, and whose unique goal is to accelerate the development and deliver innovative therapeutic solutions to cancer patients.”
While Tel Aviv University graduate Dr Moore’s appointment with the Paris-headquartered company is effective immediately, Dr McEwan will join Ipsen on November 1st. Both R&D leaders will report to Dr. Alexandre Lebeaut, Executive Vice-President R&D and Chief Scientific Officer.
Dr Moore brings with him a wealth of experience from large multinationals including Bristol-Myers Squibb. Sanofi-Aventis and GlaxoSmithKline. Commenting Lebeaut said: “Yan is an outstanding biopharmaceutical executive who brings over 18 years of industry experience in oncology development across solid tumors, hematology‐oncology, gene and immune‐therapy. In his new role, Yan will lead and further strengthen our global oncology development powerhouse.”
Meanwhile McEwan, the author of more than 900 articles in peer reviewed journals and past President of the Society of Nuclear Medicine and Molecular Imaging, joins the organisation from the University of Alberta in which he held positions as Professor in the Department of Oncology and Adjunct Professor for the Department of Radiology and Diagnostic Imaging.
Lebeaut noted: “Sandy is a world-renowned expert in oncology and nuclear medicine who brings to Ipsen unique experience in this field. He will play a defining role in the acceleration of the development of Ipsen’s radiotherapeutics pipeline, providing strategic direction and managing the execution of the global clinical development of both satoreotide tetraxetan (IPN01072) and Satoreotide Trizoxetan (IPN01070) and also IPN01087 programs. Sandy will build and maintain trustworthy relationships with external oncology and nuclear medicine experts, academic networks, and professional organizations.”